T1	PROC 82 127	Ensayo clínico fase IV, abierto, aleatorizado
T2	DISO 174 188	neurotoxicidad
#1	AnnotatorNotes T2	C0235032; Neurotoxicity Syndromes; Injury or Poisoning
T3	CHEM 208 216	abacavir
#2	AnnotatorNotes T3	C0663655; abacavir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T4	CHEM 217 227	lamivudina
#3	AnnotatorNotes T4	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	CHEM 228 240	dolutegravir
#4	AnnotatorNotes T5	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
T6	ANAT 247 271	sistema nervioso central
#5	AnnotatorNotes T6	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T7	CHEM 340 351	alafenamida
T8	PROC 293 329	pauta de tratamiento antirretroviral
T9	CHEM 352 365	emtricitabina
#6	AnnotatorNotes T9	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T10	CHEM 366 375	darunavir
#7	AnnotatorNotes T10	C1435444; darunavir; Organic Chemical · Pharmacologic Substance
T11	CHEM 376 386	cobicistat
#8	AnnotatorNotes T11	C3177235; cobicistat; Organic Chemical · Pharmacologic Substance
T12	PROC 460 473	diagnosticado
#9	AnnotatorNotes T12	C0011900; Diagnosis; Diagnostic Procedure
T13	PROC 490 510	técnicas serológicas
T14	PROC 525 552	Tratamiento antirretroviral
#10	AnnotatorNotes T14	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T15	CHEM 564 567	ABC
T16	PROC 691 705	consentimiento
#11	AnnotatorNotes T16	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T17	CHEM 568 571	3TC
#12	AnnotatorNotes T17	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T18	PROC 851 860	analítica
#13	AnnotatorNotes T18	C0002778; Analysis of substances; Laboratory Procedure | C0814047; biological analysis and measurement; Laboratory Procedure
T19	CHEM 572 575	DTG
T20	PROC 1043 1052	analítica
#14	AnnotatorNotes T20	C0002778; Analysis of substances; Laboratory Procedure | C0814047; biological analysis and measurement; Laboratory Procedure
T21	PROC 1063 1072	analítica
#15	AnnotatorNotes T21	C0002778; Analysis of substances; Laboratory Procedure | C0814047; biological analysis and measurement; Laboratory Procedure
T22	PROC 1293 1326	cuestionario de calidad del sueño
#16	AnnotatorNotes T22	C4706281; Assessment using Pittsburgh Sleep Quality Index; Health Care Activity
T23	DISO 1267 1286	trastorno del sueño
#17	AnnotatorNotes T23	C0037317; Sleep disturbances; Sign or Symptom | C0851578; Sleep Disorders; Mental or Behavioral Dysfunction
T24	DISO 1471 1483	intolerancia
#18	AnnotatorNotes T24	C0277585; Intolerance to drug; Pathologic Function
T25	DISO 1462 1469	Alergia
#19	AnnotatorNotes T25	C1527304; Allergic Reaction; Pathologic Function
T26	DISO 1589 1616	infecciones activas del SNC
T27	ANAT 1613 1616	SNC
#20	AnnotatorNotes T27	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T28	DISO 1620 1628	Psicosis
#21	AnnotatorNotes T28	C0033975; Psychotic Disorders; Mental or Behavioral Dysfunction
T29	DISO 1637 1652	depresión mayor
#22	AnnotatorNotes T29	C1269683; Major Depressive Disorder; Mental or Behavioral Dysfunction
T30	DISO 1657 1676	síntomas psicóticos
T31	CHEM 1561 1564	TAF
T32	DISO 1679 1698	ideación autolítica
T33	DISO 1701 1709	Demencia
#23	AnnotatorNotes T33	C0497327; Dementia; Mental or Behavioral Dysfunction
T34	DISO 1712 1726	retraso mental
#24	AnnotatorNotes T34	C0025362; Mental Retardation; Mental or Behavioral Dysfunction | C3714756; Intellectual Disability; Mental or Behavioral Dysfunction
T35	CHEM 1565 1568	FTC
#25	AnnotatorNotes T35	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T36	PROC 1751 1762	diagnóstico
#26	AnnotatorNotes T36	C0011900; Diagnosis; Diagnostic Procedure
T37	DISO 1827 1839	Enfermedades
#27	AnnotatorNotes T37	C0012634; Disease; Disease or Syndrome
T38	PROC 1870 1884	procedimientos
#28	AnnotatorNotes T38	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T39	PROC 1944 1958	procedimientos
#29	AnnotatorNotes T39	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T40	PROC 2075 2096	método anticonceptivo
#30	AnnotatorNotes T40	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T41	DISO 1729 1746	Consumo de drogas
T42	CHEM 314 329	antirretroviral
#31	AnnotatorNotes T42	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T43	DISO 410 413	VIH
#32	AnnotatorNotes T43	C0458074; Human immunodeficiency virus (HIV) status; Finding
T44	DISO 477 480	VIH
#33	AnnotatorNotes T44	C0458074; Human immunodeficiency virus (HIV) status; Finding
T45	CHEM 537 552	antirretroviral
#34	AnnotatorNotes T45	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T46	PROC 606 621	Carga viral VIH
#35	AnnotatorNotes T46	C1168369; HIV viral load; Laboratory Procedure
T47	PROC 784 791	viremia
#36	AnnotatorNotes T47	C1261478; Viral load measurement; Laboratory Procedure
T48	PROC 929 944	carga viral VIH
#37	AnnotatorNotes T48	C1168369; HIV viral load; Laboratory Procedure
T49	PROC 1172 1183	carga viral
#38	AnnotatorNotes T49	C1261478; Viral load measurement; Laboratory Procedure
T50	PROC 1399 1417	carga viral de VIH
T51	DISO 1500 1525	mutaciones de resistencia
T52	DISO 1766 1771	abuso
#39	AnnotatorNotes T52	C0013146; Drug abuse; Mental or Behavioral Dysfunction
T53	DISO 1774 1785	dependencia
#40	AnnotatorNotes T53	C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T54	CHEM 1569 1572	DRV
T55	Date 13 17	2018
T57	LIVB 442 450	Paciente
#41	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	Age 451 459	>18 años
T60	Date 553 559	actual
T61	Duration 584 602	al menos 4 semanas
T62	LIVB 618 621	VIH
#42	AnnotatorNotes T62	C0019682; HIV; Virus
T63	Duration 645 664	al menos 12 semanas
T64	Duration 760 779	al menos 12 semanas
T66	LIVB 827 835	paciente
#43	AnnotatorNotes T66	C0030705; Patients; Patient or Disabled Group
T67	Date 871 879	reciente
T68	Duration 881 892	≤ 4 semanas
T69	LIVB 941 944	VIH
#44	AnnotatorNotes T69	C0019682; HIV; Virus
T70	Neg_cue 1022 1024	no
T71	Duration 1073 1093	supere las 4 semanas
T72	LIVB 1206 1214	paciente
#45	AnnotatorNotes T72	C0030705; Patients; Patient or Disabled Group
T73	PHYS 1321 1326	sueño
#46	AnnotatorNotes T73	C0037313; Sleep; Organism Function
T74	LIVB 1414 1417	VIH
#47	AnnotatorNotes T74	C0019682; HIV; Virus
T75	Duration 1435 1457	las últimas 12 semanas
T77	PHYS 1679 1687	ideación
#48	AnnotatorNotes T77	C0392348; ideation; Mental Process
T79	LIVB 1974 1993	Mujeres embarazadas
#49	AnnotatorNotes T79	C0033011; Pregnant Women; Population Group
T80	LIVB 1996 2005	lactantes
#50	AnnotatorNotes T80	C4316174; Patients who are breastfeeding; Patient or Disabled Group
T81	LIVB 2016 2038	mujeres en edad fértil
#51	AnnotatorNotes T81	C4324275; Woman of childbearing potential; Population Group
T82	Age 2027 2038	edad fértil
T83	PHYS 1982 1993	embarazadas
#52	AnnotatorNotes T83	C0032961; Pregnancy; Organism Function
T84	Neg_cue 2043 2045	no
T85	LIVB 612 617	viral
#53	AnnotatorNotes T85	C0042776; Virus; Virus
T86	LIVB 935 940	viral
#54	AnnotatorNotes T86	C0042776; Virus; Virus
T87	LIVB 1178 1183	viral
#55	AnnotatorNotes T87	C0042776; Virus; Virus
T88	PHYS 1281 1286	sueño
#56	AnnotatorNotes T88	C0037313; Sleep; Organism Function
T89	LIVB 1405 1410	viral
#57	AnnotatorNotes T89	C0042776; Virus; Virus
T90	PHYS 1720 1726	mental
#58	AnnotatorNotes T90	C0229992; Psyche structure; Mental Process
T59	CHEM 1740 1746	drogas
#59	AnnotatorNotes T59	C0086190; Illicit Drugs; Hazardous or Poisonous Substance
T56	PROC 990 1009	visita de selección
#60	AnnotatorNotes T56	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
A3	Assertion T20 Negated
A5	Population_data T81 Age
A6	Assertion T40 Negated
A1	Status T26 History_of
A4	Status T25 History_of
#61	AnnotatorNotes T60	C0521116; Current (present time); Temporal Concept 
#62	AnnotatorNotes T1	C0282462; Phase 4 Clinical Trials; Research Activity + C1709323; Open Label Study; Research Activity + C0034656; Randomization; Research Activity
#63	AnnotatorNotes T19	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
#64	AnnotatorNotes T50	C1168369; HIV viral load; Laboratory Procedure
#65	AnnotatorNotes T41	C0242510; Drug usage; Mental or Behavioral Dysfunction
R1	Negation Arg1:T70 Arg2:T20	
A7	Status T24 History_of
T65	Spec_cue 1844 1850	puedan
T76	CONC 1851 1861	interferir
A8	Assertion T76 Speculated
#66	AnnotatorNotes T76	C0521102; Interferes with; Functional Concept
R2	Speculation Arg1:T65 Arg2:T76	
T78	Neg_cue 1899 1915	Inhabilidad para
T91	Observation 1916 1958	completar cualquiera de los procedimientos
A9	Assertion T91 Negated
R3	Negation Arg1:T78 Arg2:T91	
R4	Negation Arg1:T84 Arg2:T40	
T92	Observation 153 167	reversibilidad
#67	AnnotatorNotes T92	C0679253; disease reversibility; Finding
R5	Combined_with Arg1:T3 Arg2:T4	
R6	Combined_with Arg1:T4 Arg2:T5	
R7	Causes Arg1:T3 Arg2:T2	
R8	Location_of Arg1:T6 Arg2:T2	
R9	Used_for Arg1:T42 Arg2:T8	
R10	Combined_with Arg1:T7 Arg2:T9	
R11	Combined_with Arg1:T9 Arg2:T10	
R12	Combined_with Arg1:T10 Arg2:T11	
R13	Before Arg1:T3 Arg2:T7	
R14	Used_for Arg1:T3 Arg2:T8	
R15	Used_for Arg1:T7 Arg2:T8	
#68	AnnotatorNotes T7	C3713958; tenofovir alafenamide; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
R16	Causes Arg1:T8 Arg2:T2	
R17	Has_Age Arg1:T57 Arg2:T58	
R18	Experiences Arg1:T57 Arg2:T44	
R19	Experiences Arg1:T57 Arg2:T13	
R20	Before Arg1:T13 Arg2:T12	
#69	AnnotatorNotes T13	C0036743; Serologic tests; Laboratory Procedure
R22	Used_for Arg1:T45 Arg2:T14	
R23	Combined_with Arg1:T15 Arg2:T17	
R24	Combined_with Arg1:T17 Arg2:T19	
#70	AnnotatorNotes T15	C0663655; abacavir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
R25	Has_Duration_or_Interval Arg1:T15 Arg2:T61	
R26	Has_Duration_or_Interval Arg1:T17 Arg2:T61	
R27	Has_Duration_or_Interval Arg1:T19 Arg2:T61	
R28	Has_Duration_or_Interval Arg1:T45 Arg2:T61	
R29	Used_for Arg1:T15 Arg2:T14	
R30	Overlap Arg1:T15 Arg2:T60	
R21	Overlap Arg1:T45 Arg2:T60	
R31	Overlap Arg1:T17 Arg2:T60	
R32	Overlap Arg1:T19 Arg2:T60	
T93	Result_or_Value 622 636	< 50 copias/mL
R33	Has_Result_or_Value Arg1:T46 Arg2:T93	
R34	Has_Duration_or_Interval Arg1:T46 Arg2:T63	
R35	Before Arg1:T46 Arg2:T16	
T94	Quantifier_or_Qualifier 726 745	dos determinaciones
R36	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T94	
R37	Has_Quantifier_or_Qualifier Arg1:T47 Arg2:T94	
T95	Result_or_Value 792 806	< 50 copias/mL
R38	Has_Result_or_Value Arg1:T47 Arg2:T95	
R39	Has_Duration_or_Interval Arg1:T46 Arg2:T64	
R40	Has_Duration_or_Interval Arg1:T47 Arg2:T64	
R41	Has_Duration_or_Interval Arg1:T47 Arg2:T63	
R42	Before Arg1:T47 Arg2:T16	
R43	Overlap Arg1:T18 Arg2:T67	
R44	Experiences Arg1:T66 Arg2:T18	
R45	Overlap Arg1:T18 Arg2:T68	
R46	Overlap Arg1:T48 Arg2:T67	
R47	Overlap Arg1:T48 Arg2:T68	
R48	Experiences Arg1:T66 Arg2:T48	
R49	Before Arg1:T18 Arg2:T56	
R50	Before Arg1:T48 Arg2:T56	
R51	After Arg1:T21 Arg2:T71	
T96	PROC 1136 1145	selección
#71	AnnotatorNotes T96	C0242802; Patient Selection; Research Activity
R52	Overlap Arg1:T96 Arg2:T49	
R53	Before Arg1:T21 Arg2:T96	
R54	Before Arg1:T20 Arg2:T96	
R55	Experiences Arg1:T72 Arg2:T49	
R56	Experiences Arg1:T72 Arg2:T21	
R57	Experiences Arg1:T72 Arg2:T20	
T97	Result_or_Value 1244 1263	Valoración positiva
#72	AnnotatorNotes T97	C1446409; Positive; Finding
R59	Has_Result_or_Value Arg1:T22 Arg2:T97	
T98	Quantifier_or_Qualifier 1385 1398	al menos, una
R60	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T98	
T99	Result_or_Value 1418 1431	≥50 copias/mL
R62	Has_Result_or_Value Arg1:T50 Arg2:T99	
R63	Overlap Arg1:T50 Arg2:T75	
R64	Causes Arg1:T31 Arg2:T25	
R65	Causes Arg1:T31 Arg2:T24	
R66	Causes Arg1:T35 Arg2:T25	
R67	Causes Arg1:T35 Arg2:T24	
R68	Causes Arg1:T54 Arg2:T25	
R69	Causes Arg1:T54 Arg2:T24	
#73	AnnotatorNotes T31	C3713958; tenofovir alafenamide; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
#74	AnnotatorNotes T54	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
R70	Location_of Arg1:T27 Arg2:T26	
#75	AnnotatorNotes T26	C0007684; Central Nervous System Infection; Disease or Syndrome (?)
R71	Overlap Arg1:T29 Arg2:T30	
T100	Quantifier_or_Qualifier 1629 1635	activa
#76	AnnotatorNotes T100	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R73	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T100	
#77	AnnotatorNotes T30	C0871189; Psychotic symptom; Sign or Symptom
R75	After Arg1:T92 Arg2:T8	
T101	CONC 1819 1824	DSM-5
#78	AnnotatorNotes T101	C4236906; Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); Intellectual Product
R76	Used_for Arg1:T101 Arg2:T36	
R77	Causes Arg1:T59 Arg2:T52	
R78	Causes Arg1:T59 Arg2:T53	
R80	Experiences Arg1:T79 Arg2:T83	
R81	Has_Age Arg1:T81 Arg2:T82	
T102	Quantifier_or_Qualifier 2097 2105	adecuado
A2	Assertion T102 Negated
#79	AnnotatorNotes T102	C0205411; Adequate; Qualitative Concept
R82	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T102	
R83	Negation Arg1:T84 Arg2:T102	
R84	Experiences Arg1:T81 Arg2:T40	
R85	Experiences Arg1:T66 Arg2:T56	
#80	AnnotatorNotes T67	C0332185; Recent; Temporal Concept
#81	AnnotatorNotes T51	C5704646; Drug resistance mutation; Cell or Molecular Dysfunction
A10	Assertion T21 Hypothetical
A11	Assertion T71 Hypothetical
A12	Experiencer T66 Patient
A13	Assertion T18 Hypothetical
A14	Assertion T67 Hypothetical
A15	Assertion T68 Hypothetical
A16	Assertion T48 Hypothetical
A17	Experiencer T72 Patient
A18	Experiencer T57 Patient
A19	Experiencer T80 Patient
A20	Experiencer T81 Patient
A21	Experiencer T79 Patient
